iBASKET Modules
iBASKET (Part B). Therapeutic portion
Module 1 – Immunogenetics
Immune-checkpoint blockade in genomically selected populations
- Module leader: IGR and VHIO
- Pharma partner: Roche
The current protocol contains the Module 1 of iBASKET with the following arms:
- Arm 1A: BRCA1 or BRCA2 mutations
- Arm 1B: MLH1, MSH2, MSH6, PMS2 mutations
- Arm 1C: tumours with POLE mutation, POLD1 mutation
- Arm 1D: hypermutated tumours
- Arm 1E: tumours with other mutations in DNA-repair genes.
- Arm 1F: tumours with amplified PDL1
Module 2 – FGFR
Futibatinib in subjects with FGFR-aberrant solid tumours
- Module leader: VHIO
- Pharma partner: Taiho Oncology, Inc
The current protocol contains the Module 2 of iBASKET with the following arms:
- Arm 2A: Known pathogenic FGFR1-3 mutations.
- Arm 2B: Variants of unknown significance in FGFR1-3 with functional relevance or pathogenic FGFR4 mutations.
- Arm 2C: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio > 6) WITH high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).
- Arm 2D: Highly amplified FGFR1-3 (NGS equivalent to FISH ratio >6) WITHOUT high FGFR1-3 mRNA (above the percentile 95 for general cancer population by using Nanostring Gene expression profile in solid tumours (with the exception of gastric and breast cancer).